{"organizations": [], "uuid": "c96b790271c7d27ab134725c46f9b436139375e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180112.html", "section_title": "Archive News &amp; Video for Friday, 12 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/buzz-aradigm-corp-ladenburg-thalmann-cut/buzz-aradigm-corp-ladenburg-thalmann-cuts-rating-to-neutral-idUSL4N1P7492", "country": "US", "domain_rank": 408, "title": "BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.764, "site_type": "news", "published": "2018-01-12T21:51:00.000+02:00", "replies_count": 0, "uuid": "c96b790271c7d27ab134725c46f9b436139375e4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/buzz-aradigm-corp-ladenburg-thalmann-cut/buzz-aradigm-corp-ladenburg-thalmann-cuts-rating-to-neutral-idUSL4N1P7492", "ord_in_thread": 0, "title": "BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "linhaliq", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "ladenburg thalmann", "sentiment": "negative"}, {"name": "buzz-aradigm corp", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "ladenburg thalmann ** company", "sentiment": "none"}, {"name": "aradigm", "sentiment": "none"}, {"name": "adcom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "** Drug developer’s shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks\n** Based on -ve Adcom vote on Thursday and resulting lack of clarity wrt regulatory pathway for Linhaliq, we’re lowering our rating to “neutral” from “buy”, removing PT - Ladenburg Thalmann\n** An advisory committee to U.S. FDA voted 12-3 against co’s drug, Linhaliq, as a treatment for non-cystic fibrosis bronchiectasis with a bacterial infection\n** FDA usually takes recommendations into account when making a drug approval, but is not obligated to follow them\n** We expect it is likely Aradigm will receive a complete response letter for Linhaliq by the Jan 26 action date set by the U.S. FDA - Ladenburg Thalmann\n** Company’s stock had risen more than four-fold in 2017 (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-12T21:51:00.000+02:00", "crawled": "2018-01-13T14:42:04.004+02:00", "highlightTitle": ""}